Canaccord downgraded Akoya Biosciences (AKYA) to Hold from Buy with a $3.50 price target after Quanterix (QTRX) agreed to acquire Akoya in an all-stock transaction. Following the deal, Quanterix shareholders will own approximately 70% of the combined company and Akoya shareholders will own approximately 30%, on a fully diluted basis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Quanterix to acquire Akoya Biosciences in an all-stock transaction
- Akoya Biosciences, NeraCare enter exclusive global license agreement
- Akoya Biosciences price target lowered to $3 from $4 at Piper Sandler
- Morgan Stanley, Comerica upgraded: Wall Street’s top analyst calls
- Akoya Biosciences downgraded to Hold from Buy at Craig-Hallum